MCRB
Price
$11.87
Change
+$1.01 (+9.30%)
Updated
Jul 3 closing price
Capitalization
103.65M
30 days until earnings call
MDGL
Price
$298.87
Change
-$1.28 (-0.43%)
Updated
Jul 3 closing price
Capitalization
6.64B
31 days until earnings call
Interact to see
Advertisement

MCRB vs MDGL

Header iconMCRB vs MDGL Comparison
Open Charts MCRB vs MDGLBanner chart's image
Seres Therapeutics
Price$11.87
Change+$1.01 (+9.30%)
Volume$107.17K
Capitalization103.65M
Madrigal Pharmaceuticals
Price$298.87
Change-$1.28 (-0.43%)
Volume$108.67K
Capitalization6.64B
MCRB vs MDGL Comparison Chart in %
Loading...
MCRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MCRB vs. MDGL commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MCRB is a Hold and MDGL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (MCRB: $11.87 vs. MDGL: $298.87)
Brand notoriety: MCRB and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MCRB: 112% vs. MDGL: 34%
Market capitalization -- MCRB: $103.65M vs. MDGL: $6.64B
MCRB [@Biotechnology] is valued at $103.65M. MDGL’s [@Biotechnology] market capitalization is $6.64B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MCRB’s FA Score shows that 1 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • MCRB’s FA Score: 1 green, 4 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, MCRB is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MCRB’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 5 bullish TA indicator(s).

  • MCRB’s TA Score: 5 bullish, 4 bearish.
  • MDGL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both MCRB and MDGL are a good buy in the short-term.

Price Growth

MCRB (@Biotechnology) experienced а +24.82% price change this week, while MDGL (@Biotechnology) price change was -0.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

MCRB is expected to report earnings on Aug 05, 2025.

MDGL is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.64B) has a higher market cap than MCRB($104M). MDGL YTD gains are higher at: -3.144 vs. MCRB (-28.580). MCRB has higher annual earnings (EBITDA): -55.82M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. MCRB (58.8M). MCRB has less debt than MDGL: MCRB (89.5M) vs MDGL (120M). MDGL has higher revenues than MCRB: MDGL (317M) vs MCRB (0).
MCRBMDGLMCRB / MDGL
Capitalization104M6.64B2%
EBITDA-55.82M-376.15M15%
Gain YTD-28.580-3.144909%
P/E RatioN/AN/A-
Revenue0317M-
Total Cash58.8M843M7%
Total Debt89.5M120M75%
FUNDAMENTALS RATINGS
MCRB vs MDGL: Fundamental Ratings
MCRB
MDGL
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
64
Fair valued
PROFIT vs RISK RATING
1..100
10042
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4257
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MCRB's Valuation (28) in the Biotechnology industry is somewhat better than the same rating for MDGL (64) in the Pharmaceuticals Other industry. This means that MCRB’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for MCRB (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than MCRB’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as MCRB (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to MCRB’s over the last 12 months.

MCRB's Price Growth Rating (42) in the Biotechnology industry is in the same range as MDGL (57) in the Pharmaceuticals Other industry. This means that MCRB’s stock grew similarly to MDGL’s over the last 12 months.

MCRB's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that MCRB’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MCRBMDGL
RSI
ODDS (%)
Bearish Trend 4 days ago
84%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
79%
Momentum
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
72%
MACD
ODDS (%)
N/A
Bullish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 7 days ago
77%
Declines
ODDS (%)
Bearish Trend 24 days ago
89%
Bearish Trend 4 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
MCRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AUIAF0.16N/A
N/A
Aurania Resources, Ltd.
CARCY5.97N/A
N/A
China Resources Building Materials Technology Holdings Limited
INDFY10.76N/A
N/A
Indofood Agri Resources Ltd.
NVZMY70.91-0.71
-0.99%
NOVONESIS A S
BSEG0.01N/A
-13.53%
Big Screen Entertainment Group, Inc.

MCRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, MCRB has been loosely correlated with ORMP. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if MCRB jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MCRB
1D Price
Change %
MCRB100%
+9.30%
ORMP - MCRB
42%
Loosely correlated
+0.93%
AXON - MCRB
38%
Loosely correlated
+2.70%
AMRN - MCRB
36%
Loosely correlated
+0.48%
ARRY - MCRB
34%
Loosely correlated
+11.93%
ALNY - MCRB
34%
Loosely correlated
+0.65%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-0.43%
KANT - MDGL
62%
Loosely correlated
N/A
ALXO - MDGL
56%
Loosely correlated
+3.39%
CGEM - MDGL
50%
Loosely correlated
+0.64%
NAGE - MDGL
45%
Loosely correlated
+1.03%
IPHA - MDGL
44%
Loosely correlated
N/A
More